Welcome to Biosystemix:
Building the Bridge to Personalized Medicine
Biosystemix (privately held, founded in 2003) aims to become the leading provider of personalized medicine solutions that will transform the clinical and economic practice of medicine.
Biosystemix generates groundbreaking products for medical decision making and therapeutics through: (1) Partnerships with leading clinical institutions for the discovery of the biomolecular profiles predictive of disease and therapeutic outcomes; (2) computational and information science technologies for the modeling and prediction of clinical treatments and outcomes. Biosystemix creates high medico-economic value through products that (i) lead to more effective treatments, (ii) reduce ineffective treatments, and (iii) reduce the costs of patient care..
Biosystemix Targets Major Unmet Medical Needs
The future of medicine lies in biomolecular and information science-driven personalized care. Acquiring and interpreting the molecular and clinical data that characterize a patient will be the bases for selecting and monitoring therapies. With effective personalized medicine technologies: (i) Diseases will be characterized better and diagnosed correctly more often; (ii) better treatments more customized to the patient will be applied; and (iii) the large costs of otherwise ineffective treatments will be avoided. Through personalized medicine technologies that incorporate novel clinical and molecular information, Biosystemix products (1) increase therapeutic success due to improved treatment selection, (2) relieve stresses on healthcare systems by reducing treatment costs and hospital stays. The Biosystemix product pipeline:
READ (Risk Evaluation for AHCT Donors): Blood-based molecular diagnostic test for in-advance prevention of severe rejection in bone marrow transplantation (patent filed April 2007).
FL Test: Molecular test for the prediction of Follicular Lymphoma cancer outcomes (provisional patent filed Sep. 2007).
Vaccines Personalized Medicine: Partnership with international leader in clinical molecular immunogenomics for the discovery and development of personalized HIV and cancer vaccines.
Critical Care Personalized Medicine: Collaboration with a leading clinical center in the development of bedside tests for critical care treatment selection (very large diagnostic market opportunity).
Biosystemix was founded by Dr. Roland Somogyi and Dr. Larry D. Greller to transform clinical and molecular disease research into data-driven medical solutions. In addition to the vast amounts of medical patient information being used today, modern molecular profiling methods provide detailed data on the state and causes of an individual’s disease to an unprecedented degree. Through the molecular analysis of blood and biopsy tissue, we can access the information that will tell us with increasing precision what a patient’s disease outcome might be, and which therapeutic strategies may be most suitable.
At Biosystemix we believe that patients and clinical practitioners should be able to benefit from these novel molecular and personalized medicine technologies as soon as possible. These technologies are not only expected to lead to intensely needed increases in medical treatment successes and patient quality of life, but also to a reduction of the medical care burden, and more efficient, individually-targeted therapeutic development.
While there are many clinical molecular disease studies ongoing today, we are still challenged with bridging the substantial gap between the acquired medical research data, and the desired clinical, personalized medicine applications. The key to information-driven, personalized medicine lies in developing accurate, powerful, and reliable computational and statistical predictive models from the evidence-base of molecular and clinical patient data. These models, whether relatively simple or highly complex, can transform diagnostic, prognostic, and therapeutic decision-making. Because they capture in detail the true clinical and molecular knowledge available, they maximize the predictive power available today for medical decision support.
Biosystemix provides the technologies, data analysis services, and partnering solutions to build the bridge between molecular and clinical study data and effective personalized medicine application models. Our efficient and direct, data-driven approaches rely on advanced methods from statistics, signal processing, machine learning, pattern recognition, data mining, and mathematical modeling. Our work is carefully orchestrated with biomedical domain expertise to guide the definition and search for effective applications. Biosystemix currently provides its expertise in the form of consulting, analysis services, discovery partnerships, and reports focusing on complex predictive models for customer applications. Together with our partners we are developing novel solutions that combine biomarkers and therapeutics into personalized medicine application solutions.
Biosystemix, Ltd. © 2007